Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Pfizer’s RSV Vaccine Abrysvo Shows Strong Protection in Immunocompromised Adults, Phase III Sub-Study Reveals

Fineline Cube Aug 13, 2024

Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline...

Company Deals

TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion

Fineline Cube Aug 12, 2024

TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial...

Company Drug

Chinese NMPA Approves Hengrui Pharmaceuticals’ Generic Abraxane for Metastatic Pancreatic Cancer Treatment

Fineline Cube Aug 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Mindray Medical Forges Comprehensive Partnership with CUHK-Shenzhen School of Medicine

Fineline Cube Aug 12, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a prominent medical device company based in...

Company Drug

CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Clinical Trials in Systemic Lupus Erythematosus

Fineline Cube Aug 12, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company in China, has announced that...

Company Drug

Mabwell’s Nectin-4 Targeting ADC 9MW2821 on Path to Breakthrough Designation in China for Urothelial Carcinoma

Fineline Cube Aug 12, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Shineyo Medical Secures RMB 100 Million in Series A+ Funding for Cardiac and Vascular Devices

Fineline Cube Aug 12, 2024

Shineyo Medical, a Shanghai-based manufacturer of electrophysiological and peripheral interventional devices, has reportedly secured nearly...

Company Drug

Fujian Cosunter’s Innovative Drug GST-HG141 Exceeds Efficacy in Reducing HBV DNA in Phase II Study

Fineline Cube Aug 12, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced the successful...

Company Drug

3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608

Fineline Cube Aug 12, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau

Fineline Cube Aug 12, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced...

Company Drug

3SBio’s Subsidiary Achieves Milestone in Phase II Study for Chronic Sinusitis Treatment SSGJ-611

Fineline Cube Aug 12, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Lee’s Pharma Subsidiary Receives Green Light for Phase III Dry Eye Study and Completes Myopia Trial

Fineline Cube Aug 12, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a prominent Chinese pharmaceutical company, through its subsidiary Zhaoke...

Company

Amgen to Establish New Site in Hyderabad, India, with Focus on Technology and Digital Innovation

Fineline Cube Aug 12, 2024

Amgen (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has announced strategic plans...

Company Deals

MSD to Acquire Curon Biopharmaceutical’s CD3 x CD19 Bispecific Antibody CN201 in USD 1.3 Billion Deal

Fineline Cube Aug 12, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic acquisition agreement with Shanghai-based...

Company

Sichuan Huiyu Pharmaceutical’s Chairman Ding Zhao Faces CSRC Investigation for Short-Term Stock Trading

Fineline Cube Aug 9, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese pharmaceutical company, has disclosed that its...

Company

Fosun Pharma’s West African Project Nears First-Phase Completion, Aims for 5 Billion Drug Units Annually

Fineline Cube Aug 9, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) has announced the anticipated completion...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for Five Drug Candidates, Including IL-17A mAb for Psoriasis

Fineline Cube Aug 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company

Innovent Biologics Reports Over RMB 2 Billion in Q2 2024 Sales, Highlighting 50% YOY Growth

Fineline Cube Aug 9, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has reported a significant...

Company Medical Device

Sansure Biotech’s MTHFR Gene Detection Kit Receives NMPA Approval, Aids in Pregnancy Health Management

Fineline Cube Aug 9, 2024

Sansure Biotech Inc. (SHA: 688289), a specialist in molecular diagnostics based in China, has achieved...

Company Drug

Huadong Medicine Expands Global Footprint with Launch of Aesthetic Injection MaiLi in Singapore

Fineline Cube Aug 9, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced the international expansion...

Posts pagination

1 … 342 343 344 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.